Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
The Motley Fool January 26, 2011 Brian Orelli	Health-Care Reform Lives: Here's Where to Invest State of the Union turned investment thesis regarding health insurance companies.
Pharmaceutical Executive April 1, 2009 Jill Wechsler	Kickoff for Reform In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs.
The Motley Fool November 7, 2008 Brian Orelli	Will Obama Make Your Portfolio Healthy? The changes coming in the health-care industry could be a mixed bag of good and bad for your portfolio.
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
Managed Care October 2000 Michael Levin-Epstein	How We Got It Anyway: The Clinton Health Plan Never Died As a whole, the plan unceremoniously crashed and burned. But it still frames state and national debate about health policy, thus affecting the evolution of managed care...
The Motley Fool March 23, 2010 Brian Orelli	No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
The Motley Fool January 28, 2010 Brian Orelli	Health-Care Reform Is Dead. Probably. Breaking up the bill doesn't seem like the answer. What do insurers and pharmaceutical companies have to say?
Pharmaceutical Executive December 1, 2008 Jill Wechsler	Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers.
The Motley Fool April 12, 2010 Brian Orelli	Pay for Our Drugs or Else Is the pharmaceutical industry's muscle strong enough? In the U.S., health-care reform will increase coverage, but the reform's ability to keep prices in check is fairly limited.
The Motley Fool July 29, 2010 Brian Orelli	Buy, Sell, or Hold: Biotech Generics Generic biotech drugs are coming. Hop on.
The Motley Fool February 22, 2011 Brian Orelli	A Billion-Dollar Market to Open "Very Soon" Biosimilar drugs are finally coming to the U.S.
The Motley Fool June 25, 2007 Brian Orelli	Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note.
The Motley Fool September 23, 2008 Brian Lawler	Will Generic Biologics Get Special Treatment? While the rest of the market was lost in the financial meltdown, a little-noticed report discussing some of the biopharmaceutical bills going through Congress was released.
The Motley Fool July 31, 2009 Brian Orelli	A Health-Care Investor's Nightmare When it comes to health-care reform, no news is not good news; the House's recent plan to delay voting on a health-care reform bill until September should have investors reaching for the antacids.
The Motley Fool October 26, 2007 Brian Orelli	Investing in Follow-On Biologics Investors, while approvals of follow-on biologics in the U.S. are probably still years away, now is the time to do your research. Those that are leading the race overseas are likely to be first in line when the FDA opens its door to applications.
The Motley Fool November 2, 2009 Brian Orelli	Winners and Losers of the House Health-Care Reform Bill There's something for everyone to hate.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool December 10, 2008 Brian Orelli	Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline.
The Motley Fool May 7, 2010 Brian Orelli	Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies.
The Motley Fool February 27, 2009 Brian Orelli	Can $634 Billion Save the U.S. Health Care System? The good news is that Obama's budget includes a $634 billion down payment on getting insurance for the 48 million uninsured. The bad news is that the president has to pay for that by cutting costs in other areas.
The Motley Fool February 12, 2009 Brian Orelli	Stimulus Could Be Bitter Pill for Some Investors Health-care shareholders need to watch provisions of the stimulus bill closely.
The Motley Fool February 8, 2011 Brian Orelli	A Few Extra Years of Sales? Yes, Please! An EU-Canadian proposal could help drugmakers.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
The Motley Fool July 30, 2010 Anand Chokkavelu	5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better.
The Motley Fool January 14, 2010 Jim Mueller	Roundtable: Which Health-Care Stocks to Buy Now Three Fool analysts give you their best ideas on where to put your money after the health-care reform bill makes it out of Congress.
The Motley Fool April 4, 2011 Selena Maranjian	This Expense Could Wipe You Out You probably already realize that a significant amount of your spending in retirement will go toward health care. But you may still be surprised when you see the actual average price tag.
The Motley Fool July 23, 2010 Bryan White	3 Buys Suffering From the Health-Care Hangover Three ideas in value territory for a much-needed sector.
The Motley Fool January 20, 2010 Brian Orelli	Health-Care Reform: It's Not Over Yet Massachusetts has spoken with its election of Scott Brown to the Senate. What's up next?
The Motley Fool August 31, 2010 Brian Orelli	Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior.
The Motley Fool March 3, 2009 Brian Orelli	Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think.
The Motley Fool June 30, 2009 Brian Orelli	Following the Pack to Future Returns Mylan's playing catch up, but there's room for more.
The Motley Fool July 17, 2007 Brian Orelli	An Investor's Guide to the New PDUFA It's important for investors in drug companies to keep up with the latest clinical trial news, but policy changes in Washington can affect companies' bottom lines just as much.
The Motley Fool December 30, 2010 Brian Orelli	This NICE Deal Could Foreshadow 2011 Value-based pricing is coming. The only way to encourage lower drug costs is to get the end user to pay the cost directly.
The Motley Fool September 9, 2009 Brian Orelli	Don't Like High Drug Costs? Blame Canada. Through a combination of price controls instituted by the Patented Medicine Prices Review Board, and through government negotiations, Canada is able to keep its drug costs down for its citizens. But that doesn't make it right.
The Motley Fool October 13, 2009 Brian Orelli	Health-Care Reform: You Can't Have It Both Ways Requiring insurers to cover pre-existing conditions needs to go hand-in-hand with requiring healthy people to purchase insurance.
The Motley Fool September 17, 2009 Charly Travers	Companies That Will Thrive Under Obamacare They are out there.
The Motley Fool October 29, 2009 Brian Orelli	WellPoint Sick for Another Year Good luck in 2011?
The Motley Fool April 22, 2009 Selena Maranjian	Will Health-Care Reform Hurt Investors? The bad news here is that there's quite a bit of uncertainty around this issue, and that some health-care-focused companies may end up suffering. Read on to see who.
Pharmaceutical Executive October 1, 2008 Jill Wechsler	Part D Under Attack Congressional leaders ready campaign to curb Medicare drug plans.
The Motley Fool August 6, 2007 Brian Orelli	Cheap Drugs on the Farm The House approves a prescription-drug import provision. Investors should keep an eye on the status of the bill, because laws that hurt the drugmakers' bottom lines will hurt their stock prices as well.
The Motley Fool November 30, 2011 Brian Orelli	This $581 Doughnut Hole Costs Drugmakers It's costing drugmakers money. Can they recoup it elsewhere?
Pharmaceutical Executive April 1, 2011	Revisiting Reform Courts, Congress review policies and programs shaping drug costs and access.
The Motley Fool October 30, 2009 Brian Orelli	Come On -- They Represent Your Mom! A Republican fight with AARP proves that we're still seeing politics as usual.
The Motley Fool March 24, 2010 Matt Koppenheffer	3 Lowlights of Health-Care Reform It's barreling forward, but what will it do about costs and quality?
Managed Care October 2000 John A. Marcille	Clintons' Health Plan Legacy Felt in Today's Policy Debate Much of what he and Mrs. Clinton tried to push through Congress in the Health Security Act has squeaked through states and the public sector...
The Motley Fool August 27, 2009 Brian Orelli	Health-Care Reform: If You Can't Beat 'Em, Join 'Em? America could learn something from one country across the pond.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.